Ionis Pharmaceuticals (IONS) is High Risk but RBC Capital Likes the Setup Into ALS Data
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
